Who we are
We are the first 100% Brazilian-owned multinational pharmaceutical company, and the one that invests the most in innovation. Since our establishment in 1972, we have been promoting and marketing innovative products and services with a focus on improving people’s quality of life.
Promote access to health and quality of life with treatments at a fair price and profitable operations, which ensures the sustainable growth of the company and the sharing of value generated with employees and society.
We will be one of the 3 largest pharmaceutical companies with regional capital in Latin America, leaders in prescription drugs in Brazil and a benchmark in innovation and sustainability. With increasing profitability and 10% of the portfolio protected, 30% of sales will come from international operations.
Eurofarma is a fully Brazilian owned multinational pharmaceutical company, recognized since 1972 by the medical community and society at large for promoting access to health and quality of life with affordable, quality and innovative treatments.
With operations in 20 countries in Latin America, and 10 strategically distributed manufacturing plants in Latin America, Eurofarma is a front runner in major pharmaceutical segments including Prescription Drugs, Nonprescription Drugs, OTC, Generic Drugs, Hospital, Bidding, Oncology and Outsourcing Services. The company’s broad portfolio encompasses all medical specialties and is a benchmark for central nervous system, anti-infective and hormonal drugs.
Acknowledged for its pioneering spirit and entrepreneurial savviness since its very beginning, Eurofarma has forged national and international partnerships in different cooperation models including licenses, distribution agreements, provision of services in the production sector, joint ventures and co-development, among others. Its innovation-centered pipeline comprises over 200 projects and expansion plans for key global markets.
In addition to the high investment in R&D to come up with new products, Eurofarma invests in health innovation in a broader sense, from new technologies to optimize our processes to disruptive platforms aimed at new business models. Its commitment to innovation led to the creation of the Eurofarma Synapsis project in 2017, a partnership and incentive model for startups focused on the development of disruptive healthcare technology. In 2019, the company created the 1st EmergeLabs Eurofarma, a program bringing entrepreneurial scientists and the market together to reinforce its commitment to developing the national health and innovation ecosystem.
|Eurofarma recognizes human capital as its most important asset. The Group employs approximately 8,100 people, more than 6,000 of which are allocated in Brazil. It also has one of the largest medical sales and marketing workforces in the industry, with over 3,100 employees covering approximately 630,000 medical contacts per month.||A company based on solid values that’s growing in a sustainable manner, striving for excellence and feeding on current challenges by taking new steps as if they were the first.|
Known for having one of the best work environments since the early 2000s, Eurofarma ranked among the “Best Companies to Work For” by Exame Você S/A magazine for 10 years and made the “Época GPTW (Great Place to Work)” ranking in 2014. In 2019, the company was ranked 37th on the Great Place to Work (GPTW) list. Internationally, the company was recognized for the very first time as the best pharmaceutical company to work for in Central America in the 2020 GPTW ranking for Central America and the Caribbean.
As the only pharmaceutical company to be recognized by the Guia Exame de Sustentabilidade (Exame Sustainability Guide) on four different occasions, Eurofarma strengthened its commitment to the UN Global Compact in 2015 by pledging to support its ten principles. The initiative determines the adoption of business practices based on ethical and responsible values in the areas of environment, human rights, labor relations and anti-corruption. Through a partnership forged with the Ethos Institute in 2017, the company implemented the Sustainability in the Value Chain program with the aim of evaluating and monitoring best practices of its direct suppliers of feedstock.
The company makes social investments via the Eurofarma Institute, founded in 2006. Its social projects have served more than 105,000 people directly, primarily through complementary education, environmental education and training for youth, adults and the elderly.
Galliano and Maria Teresa Billi arrived in Brazil by ship in 1957. The Italian immigrant couple, both University of Bologna graduates, came to the country in the post-war period in search of opportunities.
After 16 years of working for the laboratories Lepetit and Richter as an industrial executive, Galliano Billi was able to fulfill his lifelong dream in 1972: starting his own company. With a notorious entrepreneurial acumen and visionary insight, he started off with a small laboratory in Interlagos, which now houses the Eurofarma Institute – the company’s social branch.
He started purchasing and restoring second-hand machinery and established Billi Farmacêutica – Eurofarma Group’s very first company. At the time, Galliano used his manufacturing expertise in the medication sector to offer production services to other pharmaceutical companies – a groundbreaking and unprecedented idea that later became what we know as outsourcing.
The company has grown a lot since then, both organically and inorganically. The group acquired other companies and products, diversified its activities, ventured into different segments, and firmly held on to its goal of becoming a large and renowned conglomerate. The group adopted the umbrella brand Eurofarma in the 1990s. Throughout this journey of accomplishments, the company faced countless adversities and challenges, without ever losing track of its goals and values. It never gave up its ethical principles and aspirations of greatness.
In a very natural process that took place in the late 1990s and early 2000s, Galliano’s son and successor, Maurizio Billi, took charge of the company he had joined in 1977 – a position he holds to this day. As chief executive and reference shareholder, it was up to him to lead the teams to maintain Eurofarma’s growth trajectory, consolidate its position in Brazil, and start the company’s internationalization project.